5th edition of CII UP Health Summit gets underway Takeda Biopharmaceuticals India Private Limited (formerly Baxalta Bioscience India Pvt Ltd) – a global values-based, R&D-driven biopharmaceutical leader in innovative healthcare solutions presented an industry perspective on equitable access to healthcare during the 5th edition of the
The intervention will benefit ~60,000 women and children in selected areas of Delhi This initiative will prioritize nutrition outcomes by deepening partnership with the government to strengthen health and ICDS systems to promote evidence-based, sustainable, multi-sectoral actions for improved quality of health and nutrition
Takeda Biopharmaceuticals India Private Limited (formerly known as Baxalta Bioscience India Private Limited), a global values-based, R&D-driven biopharmaceutical leader conducted dissemination of its public health initiatives in strengthening the health system for rare diseases (RD) in India. These initiatives aim to improve access to healthcare
Takeda Biopharmaceuticals India Private Limited (formerly known as Baxalta Bioscience India Pvt. Ltd.), a global values-based, R&D-driven biopharmaceutical leader, has been certified as a Great Place To Work® in India (March 2023 - March 2024). This certification has been awarded second time in a row to
CINRYZE™ is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE. Among adult HAE patients, 51% miss at least one day of work (mean 3.3 days), 44% students miss at least one day of school
